Clinical Trial Search

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: 1-year Progression-free Survival — 31 Participants

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants

Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Objective Response Rate — 3 Participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276

Primary: Number of Participants With Objective Response — 9 participants

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Objective Tumor Response — 0 participants

Primary: The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma — 62.7 Percentage…

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants

Primary: ORR — 13 Participants

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Percentage of Patients With an Overall Response to Study Drug — 24.3; 12.5 percentage of participants

Primary: Progression-free Survival — 72 Percent

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 24; 28; 9; 8 Participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Participants With Adverse Events — 0; 15; 15 percentage of participants

Primary: Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) — 6; 10; 11; 0 Participants

Primary: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I) — 0; 1; 2; 0 Participants

Primary: Overall Response Rate — 38 percentage of participants